Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Clinical trial NCT05935215 · RECRUITING
Trial details
- NCT number
- NCT05935215
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-28
- Primary completion
- 2028-07-21
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.